Gland Pharma Limited

A holistic objective of dispensing health through a portfolio of injectable products across various therapeutic segments and delivery systems, has helped us expand to seven manufacturing facilities in India, with a capacity of approximately 750 million units. These include four facilities with 22 production lines for finished formulations and three Active Pharmaceutical Ingredient (API) facilities. Our products are produced at world-class manufacturing facilities and conform to global compliance, regulatory and quality specifications.

We are present in sterile injectables, oncology and ophthalmic segments, and focus on complex injectables including NCE-1s, First-to-File products and 505(b)(2) filings. Our products are currently delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops; and efforts are underway to augment additional manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products. We are also in the process of including new delivery systems such as pens and cartridges into our product portfolio.

Our ethos at work is to consistently focus on meeting diverse injectable needs with high-quality products at attractive price points. On this strong plinth of looking ahead, we have successfully and repeatedly harnessed our R&D expertise in synthesizing complex molecules to produce complex injectables. Enabling us to develop niche products for diverse markets worldwide.